Yersinia pestis and the three plague pandemics

Green, Monica H.; Jones, Lori; Little, Lester K.; Schamiloglu, Uli; Sussman, George D.

doi:10.1016/s1473-3099(14)70878-3

Cited by 5 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In spite of substantial advancement in its prevention and cure, ~50,000 human cases of plague have been reported during the last two decades ( WHO, 2005 ). Worldwide, an average of 4000 human plague cases are reported every year, with outbreaks erupting from time to time which cause mass casualties ( Green et al, 2014 ). Therefore, now, World Health Organization (WHO) considered plague as a re-emerging disease ( Schrag and Wiener, 1995 ; WHO, 2005 ).…”

Section: Introductionmentioning

confidence: 99%

A Recombinant Trivalent Fusion Protein F1–LcrV–HSP70(II) Augments Humoral and Cellular Immune Responses and Imparts Full Protection against Yersinia pestis

2016

View full text Add to dashboard Cite

Plague is one of the most dangerous infections in humans caused by Yersinia pestis, a Gram-negative bacterium. Despite of an overwhelming research success, no ideal vaccine against plague is available yet. It is well established that F1/LcrV based vaccine requires a strong cellular immune response for complete protection against plague. In our earlier study, we demonstrated that HSP70(II) of Mycobacterium tuberculosis modulates the humoral and cellular immunity of F1/LcrV vaccine candidates individually as well as in combinations in a mouse model. Here, we made two recombinant constructs caf1–lcrV and caf1–lcrV–hsp70(II). The caf1 and lcrV genes of Y. pestis and hsp70 domain II of M. tuberculosis were amplified by polymerase chain reaction. Both the recombinant constructs caf1–lcrV and caf1–lcrV–hsp70(II) were cloned in pET28a vector and expressed in Escherichia coli. The recombinant fusion proteins F1–LcrV and F1–LcrV–HSP70(II) were purified using Ni-NTA columns and formulated with alum to evaluate the humoral and cell mediated immune responses in mice. The protective efficacies of F1–LcrV and F1–LcrV–HSP70(II) were determined following challenge of immunized mice with 100 LD50 of Y. pestis through intraperitoneal route. Significant differences were noticed in the titers of IgG and it’s isotypes, i.e., IgG1, IgG2b, and IgG3 in anti- F1–LcrV–HSP70(II) sera in comparison to anti-F1–LcrV sera. Similarly, significant differences were also noticed in the expression levels of IL-2, IFN-γ and TNF-α in splenocytes of F1–LcrV–HSP(II) immunized mice in comparison to F1–LcrV. Both F1–LcrV and F1–LcrV–HSP70(II) provided 100% protection. Our research findings suggest that F1–LcrV fused with HSP70 domain II of M. tuberculosis significantly enhanced the humoral and cellular immune responses in mouse model.

show abstract

Section: Introductionmentioning

confidence: 99%

A Recombinant Trivalent Fusion Protein F1–LcrV–HSP70(II) Augments Humoral and Cellular Immune Responses and Imparts Full Protection against Yersinia pestis

2016

View full text Add to dashboard Cite

show abstract

“…54,55 Scientific evidence should nevertheless be historicised just as rigorously as other forms of historical evidence. 38,56,57 By confirming both the historical presence of pathogens and their evolution, scientific evidence has reinvigorated the humanist narrative of disease history. Use of science to restructure the history of disease is essential for historians to examine how people in the past experienced disease.…”

Section: Discussionmentioning

confidence: 97%

Plagued by doubt and viral misinformation: the need for evidence-based use of historical disease images

Jones

Nevell

2016

The Lancet Infectious Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

The Justinianic Plague: an interdisciplinary review

Eisenberg¹,

Mordechai²

2019

Byz. Mod. Greek stud.

View full text Add to dashboard Cite

This article is a detailed critical review of all the major scholarly publications in the rapidly expanding field of the Justinianic Plague published from 2000 through 2018. It updates the article in this journal by Dionysios Stathakopoulos from 2000, while also providing a detailed appraisal of the state of the field across all disciplines, including: literary studies, archaeology, DNA evidence, climatology, and epidemiology. We also identify the current paradigm for the Justinianic Plague as well as survey possible avenues forward for the field in the future.1

show abstract

Yersinia pestis and the three plague pandemics

Cited by 5 publications

References 3 publications

A Recombinant Trivalent Fusion Protein F1–LcrV–HSP70(II) Augments Humoral and Cellular Immune Responses and Imparts Full Protection against Yersinia pestis

A Recombinant Trivalent Fusion Protein F1–LcrV–HSP70(II) Augments Humoral and Cellular Immune Responses and Imparts Full Protection against Yersinia pestis

Plagued by doubt and viral misinformation: the need for evidence-based use of historical disease images

The Justinianic Plague: an interdisciplinary review

Contact Info

Product

Resources

About